Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial

202051 citationsJournal Articlehybrid Open Access

Authors

UMIN Clinical Trials Registry, UMIN000013036 and Japan Registry of Clinical Trials, jRCTs031180128.

Good health and well-being

Published in: Annals of Oncology

Volume 32, Issue 1, pp. 77-84

Field-Weighted Citation Impact: 2.51